SynthesisThe Cochrane database of systematic reviews2003
Drugs for preventing lung cancer in healthy people.
Synthesis in The Cochrane database of systematic reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Drugs for preventing lung cancer in healthy people.The Cochrane database of systematic reviews · 2020Pooled it
- Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract.The Cochrane database of systematic reviews · 2012Pooled it
- Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.The Cochrane database of systematic reviews · 2012Pooled it
- Antioxidant supplements for preventing gastrointestinal cancers.The Cochrane database of systematic reviews · 2008Pooled it
- Trial
- Diverse Possibilities of Si-Based Agent, a Unique New Antioxidant.Antioxidants (Basel, Switzerland) · 2023Review
- The Anti-Leukemia Effect of Ascorbic Acid: From the Pro-Oxidant Potential to the Epigenetic Role in Acute Myeloid Leukemia.Frontiers in cell and developmental biology · 2022Review
- Risk Assessment of Oxidative Stress Induced by Metal Ions Released from Fixed Orthodontic Appliances during Treatment and Indications for Supportive Antioxidant Therapy: A Narrative Review.Antioxidants (Basel, Switzerland) · 2021Review
- Evaluation of the potential of chicoric acid as a natural food antioxidant.Experimental and therapeutic medicine · 2018Article
- Mitochondrial ROS control of cancer.Seminars in cancer biology · 2017Review
- Essential Occupational Safety and Health Interventions for Low- and Middle-income Countries: An Overview of the Evidence.Safety and health at work · 2013Article
- Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants.Oxidative medicine and cellular longevity · 2013Review
- The neglected significance of "antioxidative stress".Oxidative medicine and cellular longevity · 2012Review
- Article
- Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals.BMC cancer · 2011Article
- Strategies for reducing or preventing the generation of oxidative stress.Oxidative medicine and cellular longevity · 2011Review
- Vitamins in aging, health, and longevity.Clinical interventions in aging · 2006Review
- Systematic reviews incorporating evidence from nonrandomized study designs: reasons for caution when estimating health effects.European journal of clinical nutrition · 2005Article
- Alpha-tocopherol: roles in prevention and therapy of human disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2005Review
Corrections and comments
- Updated by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome studies have suggested a protective effect of antioxidant nutrients on lung cancer. Observational epidemiological studies suggest an association between higher dietary levels of fruits and vegetables containing beta carotene and a lower risk of lung cancer.
objectivesTo determine whether vitamins, minerals and other potential agents, alone or in combination, reduce incidence and mortality from lung cancer in healthy people. SEARCH STRATEGY: The electronic databases MEDLINE (1966-july 2001), EMBASE (1974-july 2001) and the Cochrane Controlled Trial Register (CENTRAL, Issue 3/2001) and bibliographies were searched. In addition authors of included studies were contacted to identify potentially eligible published and unpublished trials. SELECTION CRITERIA: Included studies were randomised controlled clinical trials comparing different supplements or comparing supplements with placebo, administered to healthy people with the aim of preventing lung cancer. DATA COLLECTION AND ANALYSIS: Three reviewers independently selected the trials to be included in the review and assessed the methodological quality of each trial, and two extracted data using a standardised form. For each study, relative risk and 95% confidence limits were calculated for dichotomous outcomes. MAIN
resultsFour studies were eligible for inclusion. All were population based trials, including a total of 109,394 participants. Two studies included smokers, one included workers exposed to asbestos and two studies were carried out in health professionals. A group of participants with no known risk factors for lung cancer was included in the study sample of two trials. Beta-carotene was evaluated in all trials, alone or combination with alpha-tocopherol or retinol, and one study tested alpha-tocopherol alone. Duration of treatment varied from 2 to 12 years and follow-up was from two to five years. All trials had a placebo group. For people with risk factors for lung cancer no reduction in lung cancer incidence or mortality was found in those taking vitamins alone compared with placebo (incidence of lung cancer: RR 0.98, 95% CI 0.81-1.19; lung cancer mortality: RR 0.93, 95% CI 0.73-1.19). For people with no known risk factors of lung cancer, none of the vitamins or their combinations appeared to have any effect. Combined data from three studies showed a non-statistically significant increased risk of lung cancer incidence (RR 1.11, 95% CI 0.94-1.33) and mortality (RR 1.05, 95% CI 0.87-1.28) for beta-carotene alone at pharmacological doses in groups with risk factors for lung cancer. When beta-carotene was combined with retinol, data from a single study showed that there was a statistically significant, increased risk of lung cancer incidence (RR 1.42, 95% CI 1.13-1.80) and mortality (RR 1.75, 95% CI 1.29-2.38) in people with risk factors for lung cancer who took both vitamins compared with those who took placebo. Data from also from one study showed that the combination of beta-carotene with alpha-tocopherol in people with risk factors for lung cancer was associated with a non-statistically significant increased risk of lung cancer incidence (RR 1.16, 95% CI 0.96-1.39) and mortality (RR 1.15, 95% CI 0.91-1.45). No effect was observed for total cancer incidence, mortality or all-cause mortality. REVIEWER'S
conclusionsThere is currently no evidence to support recommending vitamins such as alpha-tocopherol, beta-carotene or retinol, alone or in combination, to prevent lung cancer. A harmful effect was found for beta-carotene with retinol at pharmacological doses in people with risk factors for lung cancer (smoking and/or occupational exposure to asbestos). More research from larger trials and with longer follow-up is needed to analyse the effectiveness of other supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.